Literature DB >> 19185395

VEGF protects motor neurons against excitotoxicity by upregulation of GluR2.

Elke Bogaert1, Philip Van Damme, Koen Poesen, Joke Dhondt, Nicole Hersmus, Dora Kiraly, Wendy Scheveneels, Wim Robberecht, Ludo Van Den Bosch.   

Abstract

Influx of Ca(2+) ions through the α-amino-3-hydroxy-5-methylisoxazole propionic acid (AMPA) receptors is toxic to neurons and contributes to motor neuron degeneration observed in amyotrophic lateral sclerosis (ALS). The Ca(2+) permeability of the AMPA receptor depends on its subunit composition. If the GluR2 subunit is present in the receptor complex, the AMPA receptor is impermeable to Ca(2+). In this study, we identified vascular endothelial growth factor-A (VEGF) as a GluR2 inducing molecule. Cultured motor neurons pretreated with VEGF displayed higher GluR2 levels. This resulted in AMPA receptor currents with a low relative Ca(2+) permeability and in motor neurons that were less vulnerable to AMPA receptor-mediated excitotoxicity. This effect of VEGF was mediated through the VEGFR2 present on the motor neurons and was due to stimulation of GluR2 transcription. Intracerebroventricular treatment with VEGF similarly induced GluR2 expression in the ventral spinal cord of rats and this mechanism contributes to the protective effect of VEGF on motor neurons.
Copyright © 2008 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19185395     DOI: 10.1016/j.neurobiolaging.2008.12.007

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  37 in total

Review 1.  Gene and protein therapies utilizing VEGF for ALS.

Authors:  Orion P Keifer; Deirdre M O'Connor; Nicholas M Boulis
Journal:  Pharmacol Ther       Date:  2013-10-29       Impact factor: 12.310

2.  Modeling of growth factor-receptor systems from molecular-level protein interaction networks to whole-body compartment models.

Authors:  Florence T H Wu; Marianne O Stefanini; Feilim Mac Gabhann; Aleksander S Popel
Journal:  Methods Enzymol       Date:  2009       Impact factor: 1.600

3.  Spinal vascular endothelial growth factor induces phrenic motor facilitation via extracellular signal-regulated kinase and Akt signaling.

Authors:  Erica A Dale-Nagle; Irawan Satriotomo; Gordon S Mitchell
Journal:  J Neurosci       Date:  2011-05-25       Impact factor: 6.167

4.  Astrocytes in amyotrophic lateral sclerosis: direct effects on motor neuron survival.

Authors:  K A Staats; L Van Den Bosch
Journal:  J Biol Phys       Date:  2009-03-21       Impact factor: 1.365

Review 5.  Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis.

Authors:  Emanuele D'Amico; Pam Factor-Litvak; Regina M Santella; Hiroshi Mitsumoto
Journal:  Free Radic Biol Med       Date:  2013-06-21       Impact factor: 7.376

6.  Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: where do we stand?

Authors:  Alexandre Henriques; Claudia Pitzer; Armin Schneider
Journal:  Front Neurosci       Date:  2010-06-11       Impact factor: 4.677

Review 7.  The yin and yang of VEGF and PEDF: multifaceted neurotrophic factors and their potential in the treatment of Parkinson's Disease.

Authors:  Torsten Falk; Robert T Gonzalez; Scott J Sherman
Journal:  Int J Mol Sci       Date:  2010-08-05       Impact factor: 5.923

Review 8.  Advances in cellular models to explore the pathophysiology of amyotrophic lateral sclerosis.

Authors:  C Veyrat-Durebex; P Corcia; A Dangoumau; F Laumonnier; E Piver; P H Gordon; C R Andres; P Vourc'h; H Blasco
Journal:  Mol Neurobiol       Date:  2013-11-07       Impact factor: 5.590

Review 9.  Vascular endothelial growth factor: a neurovascular target in neurological diseases.

Authors:  Christian Lange; Erik Storkebaum; Carmen Ruiz de Almodóvar; Mieke Dewerchin; Peter Carmeliet
Journal:  Nat Rev Neurol       Date:  2016-07-01       Impact factor: 42.937

10.  Current and emerging treatments for amyotrophic lateral sclerosis.

Authors:  Stefano Zoccolella; Andrea Santamato; Paolo Lamberti
Journal:  Neuropsychiatr Dis Treat       Date:  2009-11-16       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.